HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This is not an authorized publication; it is the continuous build for version 0.1.0). This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

: ColoRectal - JSON Representation

Raw json | Download


{
  "resourceType" : "PlanDefinition",
  "id" : "ColoRectal",
  "meta" : {
    "profile" : [
      "http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition"
    ]
  },
  "text" : {
    "status" : "additional",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Plan for ColoRectal cancer. There is a single cycle with 2 drug administrations</div>"
  },
  "contained" : [
    {
      "resourceType" : "ActivityDefinition",
      "id" : "ActTragacanth",
      "meta" : {
        "profile" : [
          "http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"
        ]
      },
      "text" : {
        "status" : "additional",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Tragacanth administration, 3mg over 3 hours by continuous IV infusion</div>"
      },
      "status" : "draft",
      "productCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://nzulm.org.nz/nzmt",
            "code" : "10711851000116105",
            "display" : "Tragacanth"
          }
        ]
      },
      "dosage" : [
        {
          "text" : "3 mg over 3 hours by IV infusion",
          "route" : {
            "coding" : [
              {
                "system" : "http://snomed.info/sct",
                "code" : "180177004",
                "display" : "continuous intravenous infusion"
              }
            ]
          },
          "doseAndRate" : [
            {
              "doseQuantity" : {
                "value" : 3,
                "system" : "http://unitsofmeasure.org",
                "code" : "mg"
              },
              "rateQuantity" : {
                "value" : 3,
                "system" : "http://unitsofmeasure.org",
                "code" : "h"
              }
            }
          ]
        }
      ]
    }
  ],
  "extension" : [
    {
      "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
      "valueMarkdown" : "Only for women"
    },
    {
      "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer",
      "valueMarkdown" : "Developed with the best of intentions."
    },
    {
      "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-regimen-type",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "dummy"
          }
        ],
        "text" : "Folfox"
      }
    },
    {
      "extension" : [
        {
          "url" : "factor",
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://snomed.info/sct",
                "code" : "TOUPDATE-SUPPORT4",
                "display" : "Diarrhoea risk"
              }
            ]
          }
        },
        {
          "url" : "value",
          "valueCodeableConcept" : {
            "text" : "low"
          }
        }
      ],
      "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
    },
    {
      "extension" : [
        {
          "url" : "factor",
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://snomed.info/sct",
                "code" : "TOUPDATE-SUPPORT8",
                "display" : "AntiFungal Prophylaxis"
              }
            ]
          }
        },
        {
          "url" : "value",
          "valueCodeableConcept" : {
            "text" : "low"
          }
        }
      ],
      "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
    },
    {
      "extension" : [
        {
          "url" : "factor",
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://snomed.info/sct",
                "code" : "TOUPDATE-SUPPORT2",
                "display" : "Hypersensitivity / Infusion related reaction ris"
              }
            ]
          }
        },
        {
          "url" : "value",
          "valueCodeableConcept" : {
            "text" : "low"
          }
        }
      ],
      "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
    }
  ],
  "url" : "http://hl7.org.nz/fhir/ig/cca/PlanDefinition/ColoRectal",
  "version" : "0.1.0",
  "title" : "Colorectal Adjuvant FOLFOX (a7)",
  "type" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
        "code" : "clinical-protocol"
      }
    ]
  },
  "status" : "active",
  "_status" : {
    "extension" : [
      {
        "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-additional-plan-status",
        "valueCode" : "review"
      }
    ]
  },
  "experimental" : false,
  "date" : "2020-06-29T20:14:18.417+12:00",
  "publisher" : "Te Aho o Te Kahu, Cancer Control Agency",
  "description" : "A drug treatment regimen for Colorectal cancer. Plan is still under review.",
  "useContext" : [
    {
      "code" : {
        "system" : "http://terminology.hl7.org/CodeSystem/usage-context-type",
        "code" : "focus"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "781382000",
            "display" : "Colorectal cancer"
          }
        ]
      }
    }
  ],
  "relatedArtifact" : [
    {
      "type" : "citation",
      "display" : "test",
      "url" : "http://www.ncbi.nlm.nih.gov/pubmed/23434"
    },
    {
      "type" : "citation",
      "display" : "test2",
      "url" : "http://www.ncbi.nlm.nih.gov/pubmed/34324"
    }
  ],
  "action" : [
    {
      "extension" : [
        {
          "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
          "valueMarkdown" : "Ensure not pregnant before starting"
        }
      ],
      "title" : "This is the only cycle in the regimen.",
      "description" : "Administration of Cabergoline and Tragacanth. Cycle length 14 days",
      "timingTiming" : {
        "repeat" : {
          "count" : 1,
          "duration" : 14,
          "durationUnit" : "d"
        }
      },
      "selectionBehavior" : "all",
      "action" : [
        {
          "extension" : [
            {
              "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
              "valueMarkdown" : "Keep a close eye for side effects"
            },
            {
              "extension" : [
                {
                  "url" : "day",
                  "valueInteger" : 1
                },
                {
                  "url" : "instructions",
                  "valueString" : "Specific instructions for the day 1 administration"
                }
              ],
              "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
            },
            {
              "extension" : [
                {
                  "url" : "day",
                  "valueInteger" : 4
                },
                {
                  "url" : "instructions",
                  "valueString" : "Specific instructions for the day 4 administration"
                }
              ],
              "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
            }
          ],
          "description" : "2mg of Cabergoline daily on days 1 and 4 by IV Infusion over 20 minutes",
          "definitionCanonical" : "#act-cabergoline"
        },
        {
          "extension" : [
            {
              "extension" : [
                {
                  "url" : "day",
                  "valueInteger" : 2
                },
                {
                  "url" : "instructions",
                  "valueString" : "Specific instructions for the day 2 administration"
                }
              ],
              "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
            },
            {
              "extension" : [
                {
                  "url" : "day",
                  "valueInteger" : 3
                },
                {
                  "url" : "instructions",
                  "valueString" : "Specific instructions for the day 3 administration"
                }
              ],
              "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
            },
            {
              "extension" : [
                {
                  "url" : "day",
                  "valueInteger" : 4
                },
                {
                  "url" : "instructions",
                  "valueString" : "Specific instructions for the day 4 administration"
                }
              ],
              "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
            }
          ],
          "description" : "3mg of Tragacanth daily on days 2,3 and 4 by IV Infusion over 3 hours",
          "definitionCanonical" : "#act-tragacanth"
        }
      ]
    }
  ]
}